BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Abstract Introduction: CD19-directed CAR T cell therapies have redefined treatment paradigms for B-cell malignancies. However, relapse is common and often associated with loss of CD19 expression. Patients who relapse after or are ineligible for CD19-targeted therapies face limited treatment options and poor outcomes. We have developed CAR T cells against the B-cell activating factor receptor (BAFF-R), a functionally important receptor expressed on both normal and malignant B cells. Unlike CD19 and CD20, BAFF-R plays a critical role in B-cell function and survival, making therapeutic escape via antigen downregulation less likely. Importantly, BAFF-R is expressed in CD19-negative relapse samples, supporting its relevance in settings where CD19-targeted therapies fail (Qin et al., Sci Transl Med. 2019). PMB-CT01 is a novel autologous CAR T cell therapy currently under evaluation in a first-in-human phase 1 study in patients with B-cell lymphomas. Methods: We are conducting a dose-escalation phase 1 trial (NCT05370430) of PMB-CT01 in patients with relapsed/refractory (r/r) B-cell non-Hodgkin lymphomas (B-NHL). The trial has been expanded to a multicenter study. Patients were treated at either dose level 1 (DL1; 50×106 CAR T cells) or dose level 2 (DL2; 200×106 CAR T cells). The primary objective is to evaluate safety, including dose-limiting toxicities (DLTs); secondary endpoints include overall response rate (ORR), complete response (CR) rate, minimal residual disease (MRD) negativity, progression-free survival (PFS), and overall survival (OS). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are assessed per ASTCT consensus criteria. Disease response is evaluated using the Lugano 2014 criteria. Results: Seven patients have been treated so far. Diagnoses included mantle cell lymphoma (MCL; n=4), CD19- and CD20-negative T cell/histiocyte-rich large B-cell lymphoma (THRBCL; n=1), marginal zone lymphoma (MZL; n=1) and follicular lymphoma (FL; n=1). Median age was 62 years (range: 41-75), with 6/7 male patients. Patients had received 1-10 prior lines of treatment, including CD19 CAR T cells (n=4) and a CD3/CD20 bispecific antibody (n=2). Three patients were treated at DL1 and four at DL2. No DLTs occurred. All seven patients experienced only grade 1 CRS; two had grade 1 ICANS that resolved without corticosteroids. No grade ≥2 CRS or ICANS events were reported. All patients achieved CR at 1 or 3 months post-infusion (100% CR rate). Responses have been durable, with no relapses and ongoing remissions extending up to 32 months (median 17 months; range 3-32 months). Among MCL patients, 3/3 tested were MRD-negative by both high-resolution flow cytometry and next-generation sequencing (NGS) at 1 and ≥6 months post-treatment. Robust CAR T cell expansion was observed in all patients tested. Given the favorable safety profile and durable remissions observed thus far, 200x106 BAFFR-CAR T cells is expected to be the recommended dose for future studies. We anticipate that results from the completed nine-patient dose-escalation portion of the trial will be available for presentation at the meeting. Upon identification of the recommended phase 2 dose (RP2D), three histology expansion cohorts will open in parallel: 1) FL; 2) MCL; and 3) Large B-cell lymphoma (LBCL) to further assess safety and efficacy in each subtype.Conclusions: PMB-CT01 demonstrated an exceptionally favorable safety profile and 100% CR rate in r/r B-NHL patients with poor-prognosis features, including CD19-negative disease and prior CD19 CAR T cell therapy. The durability of response at both dose levels supports the potential of BAFFR-CAR T cells as a promising therapeutic option in patients who are not candidates for or have relapsed after CD19-directed therapy. Continued enrollment and follow-up are ongoing, and updated clinical and correlative data will be presented at the meeting.

Authors

Institutions

Publication Details

Journal
Blood
Published
2025-11-03
DOI
https://doi.org/10.1182/blood-2025-268
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Hazel Cheng, Elizabeth Budde, Alan Macias, Marie Hu et al.
Blood
CAR-T cell therapy research
article

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Hazel Cheng, Elizabeth Budde, Alan Macias, Marie Hu, Teresa S. Kim, Qing Liu-Michael, Joo Y. Song, Sandrine Puverel, Xiuli Wang, Stephen J. Forman, John H. Baird, Emanuela Marcucci, Larry W. Kwak, Baishakhi Barva, Lu Chen, Zhenyuan Dong, Swetha Kambhampati, Soung-chul Cha, Marissa Del Real
article en

Abstract

Abstract Introduction: CD19-directed CAR T cell therapies have redefined treatment paradigms for B-cell malignancies. However, relapse is common and often associated with loss of CD19 expression. Patients who relapse after or are ineligible for CD19-targeted therapies face limited treatment options and poor outcomes. We have developed CAR T cells against the B-cell activating factor receptor (BAFF-R), a functionally important receptor expressed on both normal and malignant B cells. Unlike CD19 and CD20, BAFF-R plays a critical role in B-cell function and survival, making therapeutic escape via antigen downregulation less likely. Importantly, BAFF-R is expressed in CD19-negative relapse samples, supporting its relevance in settings where CD19-targeted therapies fail (Qin et al., Sci Transl Med. 2019). PMB-CT01 is a novel autologous CAR T cell therapy currently under evaluation in a first-in-human phase 1 study in patients with B-cell lymphomas. Methods: We are conducting a dose-escalation phase 1 trial (NCT05370430) of PMB-CT01 in patients with relapsed/refractory (r/r) B-cell non-Hodgkin lymphomas (B-NHL). The trial has been expanded to a multicenter study. Patients were treated at either dose level 1 (DL1; 50×106 CAR T cells) or dose level 2 (DL2; 200×106 CAR T cells). The primary objective is to evaluate safety, including dose-limiting toxicities (DLTs); secondary endpoints include overall response rate (ORR), complete response (CR) rate, minimal residual disease (MRD) negativity, progression-free survival (PFS), and overall survival (OS). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are assessed per ASTCT consensus criteria. Disease response is evaluated using the Lugano 2014 criteria. Results: Seven patients have been treated so far. Diagnoses included mantle cell lymphoma (MCL; n=4), CD19- and CD20-negative T cell/histiocyte-rich large B-cell lymphoma (THRBCL; n=1), marginal zone lymphoma (MZL; n=1) and follicular lymphoma (FL; n=1). Median age was 62 years (range: 41-75), with 6/7 male patients. Patients had received 1-10 prior lines of treatment, including CD19 CAR T cells (n=4) and a CD3/CD20 bispecific antibody (n=2). Three patients were treated at DL1 and four at DL2. No DLTs occurred. All seven patients experienced only grade 1 CRS; two had grade 1 ICANS that resolved without corticosteroids. No grade ≥2 CRS or ICANS events were reported. All patients achieved CR at 1 or 3 months post-infusion (100% CR rate). Responses have been durable, with no relapses and ongoing remissions extending up to 32 months (median 17 months; range 3-32 months). Among MCL patients, 3/3 tested were MRD-negative by both high-resolution flow cytometry and next-generation sequencing (NGS) at 1 and ≥6 months post-treatment. Robust CAR T cell expansion was observed in all patients tested. Given the favorable safety profile and durable remissions observed thus far, 200x106 BAFFR-CAR T cells is expected to be the recommended dose for future studies. We anticipate that results from the completed nine-patient dose-escalation portion of the trial will be available for presentation at the meeting. Upon identification of the recommended phase 2 dose (RP2D), three histology expansion cohorts will open in parallel: 1) FL; 2) MCL; and 3) Large B-cell lymphoma (LBCL) to further assess safety and efficacy in each subtype.Conclusions: PMB-CT01 demonstrated an exceptionally favorable safety profile and 100% CR rate in r/r B-NHL patients with poor-prognosis features, including CD19-negative disease and prior CD19 CAR T cell therapy. The durability of response at both dose levels supports the potential of BAFFR-CAR T cells as a promising therapeutic option in patients who are not candidates for or have relapsed after CD19-directed therapy. Continued enrollment and follow-up are ongoing, and updated clinical and correlative data will be presented at the meeting.

BloodVol. 146(Supplement 1)
City Of Hope National Medical Center (US), University of Minnesota (US), University of California, Irvine (US), City of Hope (US)
Openalex Percentile: Top 47%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.